Diligence memo · auto-generated · as of July 2, 2026
Zeta Surgical Inc.
Zeta Surgical Inc. looks under-valued against its niche peers and is at-risk on financing cadence.
Businessfiled
Zeta Surgical Inc. operates in Pharma, based in BOSTON, MA, USA. Next-Generation Surgical Navigation and Robotics
Sub-sector tags: ai/ml, medical-devices, pharma, robotics.
Capital & rounds (filed)filed
Zeta Surgical Inc. has raised $3.1M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $1.5M on 2018-04-30.
Most recent recorded round closed around 2023-10-27.
Valuation (modeled)modeled
Provath models Zeta Surgical Inc. at approximately $7.3M (range $817K–$23M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.54× the median modeled value of Seed Pharma companies in 2022–2024 (18 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 16 months.
Last raise 2.7 yr ago; this sector typically re-raises about every 16 months.
Past due for a raise versus sector cadence — watch for distress or a bridge.
The last round stepped up 2.2× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 49% of Pharma peers (310 compared).
Modeled value ranks above 31% of those peers.
Closest niche peers: Seal Rock Therapeutics, Inc., Diligent Pharma, Inc., A28 Therapeutics, Inc., Centaurus Therapeutics, Inc., Pathfinder Oncology, Inc..
Peoplefiled
8 named people on file across officers, directors and signatories.
Risks & flagsmixed
Overdue for a raise versus sector norm — distress or bridge risk.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.